Arcutis Biotherapeutics Inc (ARQT)

Jan 12, 2025, 8:30 AM EST - 5 days ago

Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million

Jan 6, 2025, 4:00 PM EST - 11 days ago

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 15, 2024, 8:30 AM EST - 2 months ago

Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up?

Nov 7, 2024, 2:24 AM EST - 2 months ago

Arcutis Biotherapeutics, Inc. (ARQT) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:00 PM EST - 2 months ago

Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update

Oct 23, 2024, 4:00 PM EDT - 3 months ago

Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference

Oct 22, 2024, 7:36 AM EDT - 3 months ago

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4

OGN TMDX

Oct 18, 2024, 8:20 AM EDT - 3 months ago

Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

Sep 25, 2024, 1:00 AM EDT - 4 months ago

New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types

Sep 24, 2024, 8:00 AM EDT - 4 months ago

FDA Accepts Arcutis' Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

Aug 22, 2024, 5:13 PM EDT - 5 months ago

Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely

Aug 22, 2024, 8:00 AM EDT - 5 months ago

Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 15, 2024, 12:43 AM EDT - 5 months ago

Arcutis Biotherapeutics, Inc. (ARQT) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 9:00 PM EDT - 5 months ago

CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update

Aug 14, 2024, 4:00 PM EDT - 5 months ago

Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update

Jul 29, 2024, 7:35 AM EDT - 6 months ago

Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.

Jul 29, 2024, 7:30 AM EDT - 6 months ago

Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis

Jul 22, 2024, 8:00 AM EDT - 6 months ago

Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL

Jul 9, 2024, 4:53 PM EDT - 6 months ago

FDA Approves Arcutis' ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age

Jun 10, 2024, 2:30 PM EDT - 7 months ago

Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference

May 14, 2024, 7:47 PM EDT - 8 months ago

Arcutis Biotherapeutics, Inc. (ARQT) Q1 2024 Earnings Call Transcript

May 14, 2024, 4:00 PM EDT - 8 months ago

Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update

May 13, 2024, 8:00 AM EDT - 8 months ago

Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology

Apr 29, 2024, 4:00 PM EDT - 9 months ago

Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

Apr 10, 2024, 8:00 AM EDT - 10 months ago

Arcutis Appoints David Topper as Chief Financial Officer

Apr 2, 2024, 2:10 AM EDT - 10 months ago

VKTX, JANX and these biotech stocks are surging in 2024

JANX VKTX AMLX MCRB RAPT RVNC

Mar 28, 2024, 8:00 AM EDT - 10 months ago

Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference

Mar 11, 2024, 8:00 AM EDT - 11 months ago

Arcutis Promotes Todd Tucker to Chief Human Resources Officer

Mar 10, 2024, 4:00 PM EDT - 11 months ago

Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting

Mar 9, 2024, 4:00 PM EST - 11 months ago

New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction

Mar 4, 2024, 4:00 PM EST - 11 months ago

Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Mar 4, 2024, 8:00 AM EST - 11 months ago

Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting

Feb 29, 2024, 5:00 PM EST - 11 months ago

Arcutis to Present at the TD Cowen 44th Annual Health Care Conference

Feb 28, 2024, 11:30 PM EST - 11 months ago

Arcutis Announces Pricing of $150 Million Public Offering

Feb 28, 2024, 4:10 PM EST - 11 months ago

Arcutis Announces Proposed Public Offering

Feb 28, 2024, 4:00 PM EST - 11 months ago

Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan

Feb 27, 2024, 7:48 PM EST - 11 months ago

Arcutis Biotherapeutics, Inc. (ARQT) Q4 2023 Earnings Call Transcript

Feb 27, 2024, 5:50 AM EST - 11 months ago

Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 16, 2024, 8:00 AM EST - 1 year ago

Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results

Jan 31, 2024, 8:00 AM EST - 1 year ago

Arcutis to Present at the Guggenheim Healthcare Talks – 6th Annual Biotechnology Conference

Jan 31, 2024, 3:09 AM EST - 1 year ago

Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture

Jan 29, 2024, 8:00 AM EST - 1 year ago

Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial

Jan 22, 2024, 8:00 AM EST - 1 year ago

ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States

Jan 14, 2024, 4:00 AM EST - 1 year ago

ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids

Jan 14, 2024, 4:00 AM EST - 1 year ago

Majority of Individuals with Atopic Dermatitis Improved with Arcutis' Roflumilast Cream 0.15% According to New Data from Phase 3 Program

Dec 15, 2023, 5:11 PM EST - 1 year ago

FDA Approves Arcutis' ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older

Nov 29, 2023, 8:00 AM EST - 1 year ago

FDA Accepts Arcutis' Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6

Nov 13, 2023, 7:47 AM EST - 1 year ago

Arcutis Biotherapeutics: Almost There, But Needs Some Fine-Tuning

Nov 3, 2023, 8:28 AM EDT - 1 year ago

Top 5 Health Care Stocks That Are Preparing To Pump In November - Better Therapeutics (NASDAQ:BTTX), Arcutis Biotherapeutics (NASDAQ:ARQT)

HSCS SINT

Nov 3, 2023, 7:30 AM EDT - 1 year ago

Arcutis Announces Third Quarter 2023 Financial Results and Provides Business Update